| 000 | 04758nam a2200421 i 4500 | ||
|---|---|---|---|
| 999 |
_c330459 _d330459 _x1 |
||
| 001 | 330459 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102114544.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 210104s2021 si a s |||| 0|eng d | ||
| 020 | _a9789811587917 | ||
| 024 | 7 |
_a10.1007/978-981-15-8791-7 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _erda _dES-MaUEC |
||
| 050 | 4 |
_aRC660 _b2021 EB |
|
| 245 | 0 | 0 |
_aStructure and Health Effects of Natural Products on Diabetes Mellitus _cedited by Haixia Chen, Min Zhang. |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aSingapore _bSpringer Singapore _c2021 |
|
| 300 |
_a1 recurso en línea (VIII, 307 páginas) _b85 ilustraciones, 16 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aarchivo de trexto _bPDF _2rda |
||
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-11642) | |
| 490 | 0 | _aBiomedical and Life Sciences (R0) (SpringerNature-43708) | |
| 505 | 0 | _aChapter 1. Introduction of diabetes melitus and future prospects of natural products on diabetes melitus -- Chapter 2. Anoverview of hypoglycemic modern drugs -- Chapter 3. An overview of hypoglycemic biological drugs -- Chapter 4. An overview of hypoglycemic traditionaldrugs -- Chapter 5. Glycosides from natural sources in the treatment of diabetes mellitus -- Chapter 6. Isolation and Structure Elucidation of Hypoglycemic Compounds -- Chapter 7. Structural Characterization and Health Effects of Polysaccharides from Momordica charantia on Diabetes Mellitus -- Chapter 8. Effects of polysaccharides on reducing blood glucose based on gut microbiota alteration -- Chapter 9. An Overview of Polysaccharides and the influencefactors of Hypoglycemic Activity -- Chapter 10. Plant Secondary Metabolites with α-Glucosidase Inhibitory Activity. - Chapter 11. Rhinacanthin-C and Its Potential to Control Diabetes Mellitus -- Chapter 12. Regeneration of beta cells by inhibition of pro-apoptotic proteins through phytocompound in STZ induced diabetic albino wistar rats-invivo and insilico approach. - Chapter 13. Nitrogenous Compounds from Plant Origin in Management of -- Chapter 14. Plant Alkaloids with Antidiabetic Potential -- Chapter 15. The role of Alkaloids in the Management of Diabetes Mellitus -- Chapter 16. Traditional Indian Herbs for the Management of Diabetes Mellitus and their Herb-Drug Interaction Potentials: An Evidence-Based Review -- Chapter 17. Role of Micronutrients and Trace elements in Diabetes mellitus: A Review. | |
| 520 | 3 | _aThe purpose of this book is to introduce the classified chemical components of hypoglycemic compounds in natural products, summarize the recent research progress of natural products with hypoglycemic activity in the past 20 years, and provide the original analysis and development opinions of relevant scholars. Hypoglycemic compounds are to target diabetes mellitus, an important public health problem, one of four priority noncommunicable diseases (NCDs) targeted for action by world leaders. Diabetes mellitus is a common endocrine and metabolic disease, which not only causes physiological damage to patients' kidneys, cardiovascular and cerebrovascular vessels, peripheral blood vessels, nerves and eyes, but also causes mental and psychological pressure to patients. Due to the evidence that traditional medicine and natural herbal formula have advantages in treating diabetes, natural products with hypoglycemic activity have been studied extensively in recent years and have been accepted by many scholars all over the world. This book focuses on the progress on the study of the structure, hypoglycemic activities, structure-activity relationships and mechanism of a wide range of polysaccharides, flavonoids, saponins, alkaloids, terpenoids, polyphenols and other constituents. It will help students and researchers to understand current approaches and progress in the treatment of diabetes with natural products, which may also be beneficial to develop new hypoglycemic drugs. | |
| 988 | _aSpringer_BiomedLife_2021 | ||
| 650 | 7 |
_2embne _9138582 _aDiabetes |
|
| 700 | 1 |
_aChen, Haixia _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 700 | 1 |
_aZhang, Min _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9789811587900 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811587924 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811587931 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-15-8791-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE _n0 |
||
| 998 |
_b03/2021 _dz _ek _zSI |
||